Login to Your Account

Innovation vs. access not the only quandary in cancer drug pricing

By Mari Serebrov
Washington Editor

Tuesday, June 10, 2014
Shortages and the high cost of cancer drugs are putting treatment out of reach for many cancer patients in the U.S. In searching for solutions, experts at an Institute of Medicine National Cancer Policy Forum Monday looked at regulatory practices, reimbursement policies and societal attitudes that have contributed to a pricing structure that incentivizes innovation but potentially limits patient access.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription